Key Highlights

● Centene came into focus on Friday after 2027 Medicare Advantage Star Ratings showed fewer members in four-star-or-better plans.

● Centene is best known as the largest Medicaid managed-care operator and runs Medicare Advantage plans largely under WellCare.

● Humana closed at $431.87, up $44.75, while Alignment Healthcare tumbled after its largest contract slipped below four stars.

● Health care ranked behind only real estate among S&P 500 sectors on Friday as drugmakers and Vaccine developers climbed.

Centene (NYSE:CNC) came into focus on Friday after the 2027 Medicare Advantage Star Ratings, released Thursday by the Centers for Medicare and Medicaid Services, showed the insurer will have fewer members in plans rated four stars or higher, according to a media report. The report grouped Centene with Elevance Health (NYSE:ELV) as companies set to see a smaller share of members in top-rated plans.

For insurers, star ratings are more than a badge. Medicare Advantage plans rated four stars or above qualify for federal Bonus payments, and those dollars support benefits and profitability. Fewer members in such plans can mean less bonus Revenue in the plan year the ratings apply to.

Why it matters for Centene

Centene is best known as the largest operator of Medicaid managed-care plans and a major player in the Affordable Care Act marketplace, but it also runs Medicare Advantage plans, largely under its WellCare brand. Its Medicare Business is smaller than those of some rivals, yet it remains an important part of the company's diversification. Star scores also affect how attractive plans look to seniors choosing coverage, since higher-rated plans can offer richer extras.

Centene did not issue a statement on the ratings.

A tale of two insurers

The contrast with Humana (NYSE:HUM) was striking. Humana soared, closing at $431.87, up $44.75, after nearly all of its Medicare Advantage members landed in plans with four or more stars and its flagship contract was restored to four stars. Humana also reaffirmed its full-year adjusted Earnings guidance, and Barclays (NYSE:BCS) upgraded the stock to Overweight with a $515 target, according to market data.

Elsewhere, the share of CVS Health (NYSE:CVS)'s Aetna members in top-rated plans fell to roughly seven in ten from about four in five, and CVS shares came under early pressure. UnitedHealth (NYSE:UNH)'s share fell to about two-thirds from nearly four in five, though its stock finished higher. Alignment Healthcare (NASDAQ:ALHC) tumbled after the contract covering about three-quarters of its members slipped to 3.5 stars from four. Its president, Dawn Maroney, said: "We intend to pursue all available administrative remedies."

Health care's broader rally

The health care sector still had a strong day overall, rising more than most of its peers and trailing only real estate in the S&P 500. Drugmakers and vaccine developers climbed after a media report described a planned National Institutes of Health-linked cancer-vaccine initiative, lifting Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Gilead (NASDAQ:GILD).

The broader market rose. The S&P 500 gained 46.18 points to 7,811.54, the Dow added 423.31 points to 51,654.95, and the Nasdaq Composite rose 172.83 points to 27,366.17. Gainers outnumbered losers on the NYSE by about 1.65 to 1. In the background, the 10-year Treasury Yield held near a 24-year high and the University of Michigan's sentiment index slid to a five-month low of 46.3.

Centene's Own Reading of the Ratings and Any Appeals Come Next

Stocks trade Monday for Columbus Day; bond markets are closed. On the macro calendar, September consumer prices are due Wednesday, October 14, big-bank results run October 13 to 16, and the Fed meets October 27 to 28. Investors will look for Centene's own reading of the 2027 ratings and whether it seeks to appeal any contract scores, as Alignment has said it will pursue remedies. Updates from insurers during the upcoming third-quarter reporting season will show how the industry plans to respond.